



European Monitoring Centre
for Drugs and Drug Addiction

Trends, availability and access to opioid substitution treatment in the European Union, Norway, Croatia and Turkey

Alessandro Pirona, Zagreb 2012

EMCDDA


EMCDDA Reitox network:
27 EU Member States,
Croatia, Turkey and Norway



REITOX Network



The European Union



Problem opioid users (mainly heroin)

About 1.4 million:

1 in every 250 EU adults

Overall stable

Qualitative changes:
ageing cohort, polydrug use, reduction in injecting



Harms


About 7 000 reported drug-induced deaths in 2010 (decrease) — mainly opioids (3/4), male, polydrug use

Overall decrease in new HIV infections, but alerts of regional outbreaks

High prevalence of HCV among injecting drug users




Trend in estimated proportion of new (first time ever) clients entering treatment by primary drug, 2005 to 2010



Source: EMCDDA Statistical Bulletin 2012

Primary opioid users as a percentage of all reported drug treatment entrants in 2010



Source: EMCDDA Statistical Bulletin 2012

Large investments in treatment



At least 1.1 million Europeans undergo drug treatment every year

Over half undergo opioid substitution treatment

~ 710.000 OST clients

Estimated coverage rate for opioid substitution treatment in the EU: 50 %




International comparison of estimates of problem opioid users and numbers of clients in opioid substitution treatment

	Problem opioid users	Clients in opioid substitution treatment
European Union (+3)	1 400 000	710 000
Australia	90 000	43 000
Canada	80 000	22 000
China	2 500 000	242 000
Russia	1 600 000	0
USA	1 200 000	660 000


NB: Year: 2009-2010, except for Canada (reference year is 2003).
Sources: EMCDDA (2011), Arfken et al. (2010), Chalmers et al. (2009), UNODC (2010), Yin et al. (2010), Popova et al. (2006).



Share of clients in methadone (MMT) and buprenorphine-based treatments in EU-30




Year of OST introduction in Member States



Sources: EMCDDA SB 2011 HSR 1

Estimated number of clients in opioid substitution treatment (OST) in EU 15–12, 1993–2010



Sources: EMCDDA Statistical Bulletin 2012 HSR Figure 2


emcdda.europa.eu

Clients in opioid substitution treatment in the 15 pre- 2004 and the 12 newer EU Member States — estimated numbers and indexed trends




Source: EMCDDA Annual Report 2012

Proportion of adult population and OST rate/100.000 in EU 15 and EU 12




Sources: EMCDDA Statistical Bulletin 2012 HSR 10

Opioid substitution treatment clients as a percentage of the estimated number of problem opioid users (2010)




Opioid substitution treatment clients as a percentage of the overall number of problem opioid users in treatment



Sources: EMCDDA Annual Report 2012


OST waiting times in the EU



Sources: EMCDDA SQ27 Part 1 2008/2010


emcdda.europa.eu

Provision of opioid substitution treatment by office-based general practitioners (GPs) - 2010



Source: EMCDDA Annual Report


Percentage of prison population in OST (2008)



Sources: EMCDDA SB 2011 HSR 9 and CoE SPACE I Survey 2007

emcdda.europa.eu



East versus West Europe: morphine consumption, average milligram per capita, 1980–2006



Sources: International Narcotics Control Board; United Nations population data
By: Pain & Policy Studies Group, University of Wisconsin/WHO Collaborating Center, 2008




Trends in mean age of overdose deaths



Source: EMCDDA Statistical Bulletin 2012

emcdda.europa.eu

Registrations for methadone treatment in the Netherlands by age group, 1999–2009



Source: LADIS 2010

Challenges and needs



Ageing clients

HepC / polydrug use (inc. tobacco and alcohol).

Impact of long term illness on costs/service models

Sustainable funding

Misuse of OST medications

Quality of treatment

Greater focus on (re)integration



EMCDDA publications

drug situation > publications



Annual report




Selected Issue



Drugnet Europe



Country overviews



Statistical bulletin

EMCDDA series 23s

Insights – findings of studies and research projects on topical issues
 Monographs – specialised publications containing scientific papers
 Manuals – practical handbooks for those working in the drugs field
 Risk assessments – reports on new substances entering the illicit drug market
 Selected issues – in-depth reviews of topical interest

EMCDDA
INSIGHTS
9

EMCDDA
MONOGRAPHS
8 VOLUME

EMCDDA
MANUALS
3

EMCDDA
RISK ASSESSMENTS
6

EMCDDA
SELECTED ISSUE
2008



emcdda.europa.eu/events/2012/annual-report
emcdda.europa.eu